基础医学与临床2012，Vol.32Issue(12)：1456-1460,5.
多西他赛联合顺铂及氟尿嘧啶(DCF)改良方案治疗晚期胃癌疗效观察
The efficacy of modified docetaxel, cisplatin and 5-fluorouracil combination chemotherapy in advanced gastric cancer
周娜 1应红艳 1宁晓红 1周建凤 1赵林1
作者信息
摘要
Abstract
Objective To assess the efficacy of modified docetaxel, cisplatin and 5 -fluorouracil ( mDCF) chemotherapy in patients with advanced gastric adenocarcinoma. Methods Since January 2006, 45 patients with advanced gastric cancer were enrolled and treated with mDCF protocol. The mDCF protocol included docetaxel 60 mg/m2 on dl, cisplatin 12 mg/m on dl ~5 and 5-fluorouracil 2 500 mg/m2 continuous infusion (civ) for 120 h, at an interval of 3 weeks. The primary endpoint was progression-free survival ( PFS ) and the secondary endpoints were overall survival (OS) , response rate(RR) and side effects. Results In 40 patients who received mDCF as first-line palliative chemotherapy, no patient achieved complete response, 7(17.5%) had partial response, 9(47.5%) had stable disease, and 14(35%) showed progressive disease. Overall response rate was 17. 5% (95% CI 7. 5% ~ 30. 0% ) and disease control rate was 65. 0% (95% CI 50. 0% -11.5%). Median PFS was 5. 2 months(95% CI 3. 6 ~6. 8 months)and median OS was 11. 0 months(95% CI 6. 9 ~ 15. 1 months). In 5 patients who received mDCF as second-line palliative chemotherapy, 3 achieved stable disease and 2 had progressive disease. Median PFS was 5. 3 months(95% CI 0 ~ 11. 3 months) and median OS was 8. 5 months(95% CI 0 ~ 17. 1 months). Major side effects were hematologic effects. The rates of grade 3/4 neutropenia, neutropenia with fever, nausea, vomiting and diarrhea were 26. 7% ,11. 1% , 8. 9% , 8. 9% and 11. 1% respectively. Conclusions
The mDCF regimen is effective with a folerable toxicity profile.关键词
晚期胃癌/化疗/多西他赛/顺铂/氟尿嘧啶Key words
advanced gastric cancer/ chemotherapy/ docetaxel/ cisplatin/ 5-fluorouracil分类
医药卫生引用本文复制引用
周娜,应红艳,宁晓红,周建凤,赵林..多西他赛联合顺铂及氟尿嘧啶(DCF)改良方案治疗晚期胃癌疗效观察[J].基础医学与临床,2012,32(12):1456-1460,5.
